Senzime Expands US Sales Team and Signs Additional Distribution Agreements

News provided by

Jun 24, 2020, 03:31 ET

UPPSALA, Sweden, June 24, 2020 /PRNewswire/ -- Senzime AB (publ) today announces that the company has initiated its Sales Ramp Up in the US to establish a direct sales force in key territories and that the company has signed distribution agreements for the Midwest and Northwest territories.

"I am proud to say that our strategy is now materializing in the US. Bringing distributors Clinical Technology and Co-Medical on board together with a direct sales team gives us a strong and agile position to transform the US market and introduce the cutting-edge TetraGraph technology to physicians nationwide", says Pia Renaudin, CEO Senzime.

Senzime Inc.'s President & General Manager Christopher Estes has together with Neal Smith, US VP Sales initiated the recruitment of a direct sales force that will be ready to meet accumulated demands as US hospitals now are restarting elective surgery procedures.

The US is the largest medical device market in the world representing 40 percent of global sales. By 2023, it is expected to grow to $208 billion. The country has more than 6,000 hospitals.

Senzime's TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph is based on over 10 years of R&D and uses advanced algorithms and EMG-technology to stimulate, analyze and display the patient's muscle function in real-time.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Tel: +46 (0)70-813 34 17, email: [email protected]

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, [email protected] is Certified Adviser for Senzime. www.senzime.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/senzime/r/senzime-expands-us-sales-team-and-signs-additional-distribution-agreements,c3140719

The following files are available for download: